Esubond Injection (Ibandronate Sodium Hemihydrate)

Adult administration

3 mg is administered intravenously once every 3 months for 15-30 seconds. If a scheduled dose is missed, inject as soon as possible and continue regular doses every 3 months thereafter.

This medication must be administered intravenously, and care must be taken to avoid administration into an artery or around a vein, as it may cause tissue damage. It should not be used in patients with an allergy to this medication or its other components, or in those with untreated hypocalcemia. Gastrointestinal symptoms such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation may occur during the treatment. Musculoskeletal symptoms such as muscle pain, joint pain, and musculoskeletal pain may also be experienced, and some patients have reported neurological and skin adverse reactions such as headache or rash. Some patients may experience flu-like symptoms including fever, chills, fatigue, and muscle pain after administration of this medication, although these symptoms are usually temporary and mild. Calcium levels may temporarily decrease during the use of this medication, so hypocalcemia or metabolic bone and mineral disorders should be treated before administration, and adequate calcium and vitamin D intake is important. Patients receiving dental treatment are at risk of osteonecrosis of the jaw; therefore, it is advisable to have an oral examination before drug administration and to avoid excessive dental procedures during treatment. This medication can rarely cause serious adverse effects such as osteonecrosis of the jaw, external auditory canal osteonecrosis, severe allergic reactions, skin disorders, and atypical fractures. Particularly, if pain occurs in the thigh or groin area, the possibility of atypical fractures should be suspected and evaluated immediately. There is insufficient experience with the use of this medication in pregnant or breastfeeding women, and potential risks are known, so it is safer not to use it. For the elderly, dose adjustment is not necessary, but regular examination and check-ups are needed during treatment. In cases of overdose, effects on the kidneys and liver may occur, so careful monitoring is required, and electrolyte supplementation with calcium and magnesium may be necessary. This medication must not be mixed with calcium-containing solutions or other intravenous medications and should be diluted using solutions specifically for intravenous administration. Used needles and syringes should not be reused and should be disposed of safely.

Serious side effects

• Urticaria
• severe swelling (edema)
• anaphylaxis reaction/shock
• angioedema
• facial swelling/edema
• hypersensitivity reactions
• severe allergic reactions
• Stevens-Johnson syndrome
• erythema multiforme
• bullous dermatitis

Mild side effects

• Gastritis
• diarrhea
• abdominal pain
• dyspepsia
• nausea
• constipation
• musculoskeletal pain
• joint pain
• muscle pain
• flu-like illness

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius to ensure the medication remains effective and prevents degradation.

Appearance

This injection is a colorless and clear solution contained in a colorless and clear glass prefilled syringe with a single-use needle attached.

Package unit

3 mL/prefilled syringe